Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients - Full Text View

Sponsor:	BioAlliance Pharma SA
Information provided by:	BioAlliance Pharma SA
ClinicalTrials.gov Identifier:	NCT00390780

Purpose

The purpose of this study is to evaluate the clinical cure of miconazole Lauriad 50 mg (1x50mg) Bioadhesive buccal tablets compared with clotrimazole troches (5x10mg) after 14 days of treatment (at the test of cure visit, at Day 17-19).

Condition	Intervention	Phase
HIV Infections	Drug: miconazole Lauriad	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Comparative Randomized, Double-Blind, Double-Dummy, Multicenter Study of the Efficacy and Safety of Miconazole Lauriad 50mg Administered Once a Day and Mycelex Troches (Clotrimazole 10mg) Administered Five Times a Day in the Treatment of Oropharyngeal Candidiasis in Immunocompromised Patients

Resource links provided by NLM:

MedlinePlus related topics: AIDS Yeast Infections

Drug Information available for: Miconazole nitrate Miconazole Clotrimazole

U.S. FDA Resources

Further study details as provided by BioAlliance Pharma SA:

Primary Outcome Measures:

Clinical cure (defined as a complete resolution of signs and symptoms) after 14 days of treatment at the Test of Cure visit (Day 17-Day 19) using the scoring scale of Murray

Secondary Outcome Measures:

Clinical cure at Day 7
Clinical success rates at Day 7 and at the Test of Cure visit (Day 17-19)
Microbiological cure at the Test of Cure visit (Day 17-19)
Rate of relapse at Day 35-38
General and local tolerability and oral discomfort
Duration of adhesion of miconazole Lauriad 50 mg bioadhesive buccal tablet
Systemic exposure of miconazole Lauriad 50 mg bioadhesive buccal tablet
Susceptibility of Candida species by microdilution test
Compliance

Enrollment:	578
Study Start Date:	July 2006
Study Completion Date:	January 2008
Primary Completion Date:	December 2007 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with clinical picture of oropharyngeal candidiasis
Confirmation of oropharyngeal candidiasis by candida culture positive
HIV-positive patients
Patients 18 years of age

Exclusion Criteria:

Patients with signs or symptoms of systemic candidiasis
Patients with signs or symptoms of esophagitis
Pregnant or breast-feeding women
Patients who have taken systemic antifungals within the past 30 days
Patients who have taken local antifungals within the past 7 days

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00390780

Show 27 Study Locations

Sponsors and Collaborators

BioAlliance Pharma SA

More Information

No publications provided

Study ID Numbers:	BA/2004/01/04
Study First Received:	October 19, 2006
Last Updated:	January 9, 2009
ClinicalTrials.gov Identifier:	NCT00390780 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by BioAlliance Pharma SA:

Miconazole Lauriad
Oropharyngeal candidiasis
HIV patients
Mycology

Clinical picture of Oropharyngeal candidiasis
Candida culture positive
HIV patients
Treatment Experienced

Additional relevant MeSH terms:

Anti-Infective Agents
RNA Virus Infections
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Candidiasis
Immune System Diseases
Clotrimazole
Miconazole
Acquired Immunodeficiency Syndrome
Infection
Pharmacologic Actions

Immunologic Deficiency Syndromes
Virus Diseases
Anti-Infective Agents, Local
Mycoses
HIV Infections
Therapeutic Uses
Antifungal Agents
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections

ClinicalTrials.gov processed this record on February 08, 2010